The core challenge the researchers set out to solve is a familiar one to anyone working with trace biological evidence: DNA at crime scenes, in processed foods, or in seized wildlife products is rarely pristine. Heat, chemicals, time, and environmental exposure all shred the long DNA molecules that standard analytical methods depend on. Traditional DNA barcoding, which relies on amplifying a single gene region of several hundred base pairs, often fails outright when the template DNA is broken into pieces shorter than the target. The new assay sidesteps this limitation by targeting four mitochondrial genes simultaneously: cytochrome b (Cytb), cytochrome c oxidase subunit I (COI), 16S ribosomal RNA, and 12S ribosomal RNA. Because each of these markers can be amplified as short fragments, the probability that at least one usable stretch of DNA survives in a degraded sample rises dramatically.

Mitochondrial DNA is the molecule of choice for species identification for good reason. Each cell contains hundreds to thousands of mitochondrial copies compared with just two copies of any nuclear gene, which means mitochondrial targets are far more likely to yield amplifiable material from tiny or damaged samples. Moreover, the mitochondrial genome accumulates mutations at a rate that allows closely related species to be distinguished while remaining conserved enough that universal primers can bind across a wide range of vertebrate groups. By combining four independent markers in a single multiplex reaction, the new system builds redundancy into the analysis: if one marker fails to amplify or gives an ambiguous result, the other three can still deliver a species call.

The technical architecture of the assay follows the logic of targeted amplicon sequencing. Rather than sequencing entire mitochondrial genomes, which would be wasteful and impractical for degraded templates, the system uses carefully designed primer pairs to amplify short, informative regions of the four marker genes. These amplicons are then indexed with sample-specific barcodes, pooled, and sequenced in parallel on a next-generation sequencing platform. The resulting reads are processed through a bioinformatic pipeline that filters out sequencing errors and chimeric artifacts, clusters the sequences, and matches them against reference databases. This multiplex design means dozens of samples can be analyzed simultaneously, dramatically reducing both cost and turnaround time compared with running each marker separately.

What distinguishes this study from many previous metabarcoding efforts is the systematic forensic validation that accompanied the development. Following the recommendations of the International Society for Forensic Genetics (ISFG) for non-human DNA analysis, the team subjected the assay to a battery of performance tests covering the scenarios that matter most in real casework. Sensitivity testing revealed that just 10 picograms of genomic DNA from a single species—roughly the amount of DNA in a fraction of a single cell—was sufficient to detect at least one of the four markers for all species tested. When the input was raised to 100 picograms, reliable species identification was achieved using all four markers simultaneously. These thresholds place the assay firmly in the range needed for trace evidence analysis, where investigators often work with material scraped from a single bone fragment or a smudge on a knife blade.

Mixture analysis, a critical capability for food fraud detection and wildlife trafficking cases where products may contain multiple species, produced equally impressive results. In an equimolar mixture containing ten different species with a total DNA input of just one nanogram, the assay correctly identified all ten contributors. More striking still, the system detected minor components in binary mixtures down to a 99:1 ratio, meaning a species making up only one percent of the DNA in a sample could still be flagged. This level of sensitivity for minority contributors is exactly what is needed to catch adulteration, where expensive meat or seafood is diluted with cheaper substitutes at low percentages precisely to evade detection.

The degradation studies may be the most consequential for practical applications. The researchers deliberately fragmented DNA in experimental samples and then challenged the assay with the damaged templates, alongside DNA extracted from highly processed food matrices such as cooked and commercially prepared meat products. In both scenarios, the four-marker system recovered enough sequence information to make species assignments, demonstrating that the short amplicon strategy performs as intended under the harshest conditions forensic analysts are likely to encounter. Processed foods represent one of the most common contexts for species fraud, and the ability to identify constituents in cooked, canned, or otherwise transformed products closes a significant gap in food authentication testing.

Validation extended beyond the laboratory to genuine casework samples, where the tNGS-based multiplex assay demonstrated broad-spectrum vertebrate identification across real-world evidence. The authors report that these case studies confirmed the practical value of the system for three major application areas: curbing wildlife trafficking, mitigating food fraud, and facilitating biodiversity monitoring. In wildlife trafficking investigations, the ability to identify species from seized products—whether carved ivory, dried meat, traditional medicine ingredients, or leather goods—provides prosecutors with the species-level evidence needed to establish that a crime against protected fauna occurred. For food regulators, the assay offers a screening tool capable of auditing supply chains for substitution and mislabeling. For ecologists, the same chemistry can be applied to environmental DNA samples to survey vertebrate diversity in a given habitat without needing to observe or capture animals directly.

The development team, which included collaborators from the Guangzhou Public Security Bureau, the Nanchang Police Dog Base of the Ministry of Public Security, Jinan University, and the Anti-Drug Technology Center of Guangdong Province, emphasized adherence to ethical research standards throughout the study. Animal specimens were provided by the Guangzhou Zoo and the Guangzhou Wildlife Research Center with approval from the Animal Ethics Committee of those institutions. The work was funded in part by the National Natural Science Foundation of China and the Jiangxi Provincial Key Research and Development Program, reflecting the strategic priority that Chinese research agencies have placed on forensic multi-omics and wildlife protection technology.

Looking ahead, the convergence of targeted sequencing, multiplex mitochondrial barcoding, and rigorous forensic validation points toward a future where species identification becomes as routine and standardized as human DNA profiling is today. The reference sequences used in the assay are publicly accessible through the National Center for Biotechnology Information database, and the authors have made raw data available with the publication, supporting transparency and reproducibility. As sequencing costs continue to fall and reference databases expand, systems like this one could be deployed in customs laboratories, food inspection agencies, and conservation field stations worldwide. For investigators racing to document the scale of illegal wildlife trade—a market estimated to be worth billions of dollars annually—and for consumers who deserve to know what is actually in their food, a tool that can name a species from a fragment of damaged DNA may prove to be one of the most consequential forensic innovations of the decade.

Subject of Research: A mitochondrial DNA metabarcoding system based on targeted next-generation sequencing for forensic identification of vertebrate species in degraded and mixed DNA samples

Article Title: A mitochondrial DNA metabarcoding system based on tNGS enables multiplex identification of vertebrate species in samples containing degraded and mixed DNA

Article References: Liu, X., Su, C., Wei, R., Chen, X., Le, J., Xiao, G., Chang, J., Liang, S., Wu, X., Liu, C., Liu, H., Du, W., Liu, C., & Chen, L. (2026). A mitochondrial DNA metabarcoding system based on tNGS enables multiplex identification of vertebrate species in samples containing degraded and mixed DNA. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-04024-4

Image Credits: AI Generated

DOI: 10.1007/s00414-026-04024-4

Keywords: DNA metabarcoding, targeted next-generation sequencing, mitochondrial DNA, forensic science, wildlife trafficking, food fraud, species identification, degraded DNA, cytochrome b, COI, biodiversity monitoring, vertebrate species

The assay under scrutiny is Deeplex Myc-TB, a targeted next-generation sequencing test developed to detect mutations in the tuberculosis genome that are associated with resistance to a broad range of first- and second-line anti-TB drugs. Unlike conventional rapid molecular tests, which typically interrogate only a handful of genetic regions, targeted sequencing approaches can survey dozens of genes and intergenic regions in a single run. This breadth matters enormously in clinical practice, because treatment decisions for multidrug-resistant and extensively drug-resistant tuberculosis depend on knowing, quickly and reliably, which drugs are likely to fail and which are likely to work.

To evaluate the assay, the researchers turned to an unusual but powerful resource: isolates distributed through the World Health Organization global Tuberculosis Drug-Susceptibility Testing Proficiency Testing Program, organized and administered by the TB Supranational Reference Laboratory in Antwerp, Belgium. A total of 41 isolates were included in the study. These samples are particularly valuable for verification work because they have been exhaustively characterized by reference laboratories using multiple independent methods. In this study, phenotypic drug susceptibility testing performed on Löwenstein-Jensen medium and in mycobacteria growth indicator tube culture, together with whole-genome sequencing, served as the reference standards against which the Deeplex assay was judged.

The analytical workflow was straightforward in concept. Remnant DNA extracted from the proficiency testing isolates was subjected to targeted next-generation sequencing using the Deeplex Myc-TB assay. The resulting sequence data were interpreted using the manufacturer’s Deeplex web application, and, in parallel, with TBProfiler, an open-source tool for predicting drug resistance from mycobacterial sequence data, applying a composite interpretation rule. Concordance, sensitivity, and specificity were then calculated for each drug class, providing a detailed picture of where the assay excels and where it falls short.

The headline result is striking: the Deeplex Myc-TB assay achieved 100 percent specificity across all drug targets examined. In diagnostic terms, this means that whenever the assay reported a resistance mutation, the isolate genuinely carried a mutation associated with resistance. False positives, which can lead clinicians to withhold effective drugs unnecessarily, were entirely absent from the dataset. For several drugs, the assay’s sensitivity was equally impressive. It correctly identified resistance in every tested isolate for rifampicin, detecting 17 of 17 resistant strains; for pyrazinamide, 7 of 7; for fluoroquinolones, 13 of 13; and for linezolid, 6 of 6. For isoniazid, sensitivity was 94.1 percent, with 16 of 17 resistant isolates correctly flagged.

The single isoniazid miss is instructive rather than alarming. The one false-susceptible result traced back to a specific insertion mutation in the katG gene, designated katG c.45_46insA, which fell outside the region targeted by the assay. This illustrates a fundamental property of targeted sequencing: its performance is bounded by the mutations it is designed to detect. When a resistance-conferring variant lies outside the panel’s target regions, even a technically flawless assay will report susceptibility. The finding underscores why laboratories adopting such assays must understand the local epidemiology of resistance mutations in the strains they encounter.

Performance was more mixed for the newer and repurposed drugs that have become central to modern regimens for drug-resistant tuberculosis. For clofazimine, the assay detected resistance in 4 of 5 phenotypically resistant isolates, a sensitivity of 80 percent. For bedaquiline, sensitivity dropped to 44.4 percent, with only 4 of 9 resistant strains correctly identified. In five cases, isolates that were resistant by phenotypic testing carried no resistance variants detected by the assay. The authors traced much of this gap to the biology of resistance to these drugs. Mutations in the mmpR5 gene, also known as Rv0678, a major regulator of efflux pump expression, were largely detected by the assay, but resistance mediated through the atpE gene was not identified, because that gene is not adequately covered by the assay’s target panel.

Overall concordance between the Deeplex assay and the reference standards ranged from 87.5 percent for bedaquiline to a perfect 100 percent for rifampicin, pyrazinamide, fluoroquinolones, and linezolid. Notably, the assay consistently detected several recurrent mutations associated with resistance to the different drugs, reinforcing the idea that for the common, well-established resistance mechanisms, targeted sequencing performs at or near the level of whole-genome sequencing while being faster and cheaper to deploy in routine laboratory settings. For a disease where every week of delayed or inappropriate treatment increases the risk of transmission, disease progression, and death, that speed advantage carries real clinical weight.

The implications of this verification study extend well beyond one laboratory in Uganda. Proficiency testing panels offer a rare opportunity to benchmark a diagnostic assay against isolates whose resistance profiles are known with high confidence, free from the uncertainties that complicate evaluations using routine clinical samples. By demonstrating near-perfect specificity and strong sensitivity for the cornerstone drugs of tuberculosis therapy, the study provides laboratories considering adoption of targeted next-generation sequencing with concrete, independently grounded performance data. At the same time, the documented gaps for bedaquiline and clofazimine serve as a caution against treating any single assay as a complete solution. The authors emphasize that understanding local resistance mutation patterns is essential when implementing sequencing-based resistance detection, because an assay that misses the mutations circulating in a given region will systematically underreport resistance there.

The broader context makes these findings timely. Drug-resistant tuberculosis kills thousands of people each year, and the introduction of bedaquiline, linezolid, and other newer agents has transformed outcomes for patients with resistant disease, but only when those drugs are deployed appropriately. Molecular diagnostics that can rapidly and accurately profile resistance across the full range of current and repurposed drugs are a critical link in that chain. This study shows that targeted sequencing platforms have matured to the point where they can match reference standards for the most important drugs, while also mapping precisely where the remaining blind spots lie. For laboratory directors, national tuberculosis programs, and diagnostic developers alike, the message is twofold: the technology is ready for prime time in the core of TB drug resistance testing, but careful attention to target coverage, and to the mutation landscape of the populations being served, remains indispensable.

Subject of Research: Analytical performance verification of a targeted next-generation sequencing assay for detecting drug-resistant Mycobacterium tuberculosis

Article Title: Analytical performance verification of the Deeplex Myc-TB assay using well-characterized Mycobacterium tuberculosis proficiency testing isolates

Article References: Kabahita, J. M., Lunkuse, J. M., Batte, D. N., Nakato, H. S., Namutebi, J., Kabugo, J., Adam, I., Kanyerezi, S., Makoha, C., Nsubuga, M. L., Oundo, H. R., Wenka, G. T., Sseruyange, J., Murungi, M., Kasule, G. W., Lutaaya, P., Kyokushaba, J., Byabajungu, H., Ademun, P., … Joloba, M. L. (2026). Analytical performance verification of the Deeplex Myc-TB assay using well-characterized Mycobacterium tuberculosis proficiency testing isolates. BMC Genomics. https://doi.org/10.1186/s12864-026-13336-z

Image Credits: AI Generated

DOI: 10.1186/s12864-026-13336-z

Keywords: tuberculosis, drug resistance, Deeplex Myc-TB, targeted next-generation sequencing, whole-genome sequencing, diagnostics, bedaquiline, clofazimine, isoniazid, rifampicin, proficiency testing, Uganda